AlloNK

· Artiva Biotherapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AlloNK, covering 2025-12-24 to 2025-12-24. Get the full timeline:

Most recent: Clinical Trial Update: AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. [Phase 2]

See pricing